Knowledge,attitudes and perceptions of healthcare professionals and patients towards biosimilars in Singapore

Abstract

Objective

Biosimilars offer a cost-effective alternative to biologics. Despite high (>95%) adoption in Singapore, gaps remain in healthcare professionals’ (HCPs) and patients’ knowledge and confidence. This study aims to assess the knowledge, attitudes and perceptions (KAP) of HCPs and patients regarding biosimilars in Singapore, identifying barriers and facilitators to their uptake.

Methods

A cross-sectional survey was conducted among HCPs within SingHealth institutions and patients receiving biologic/biosimilar treatment at National Cancer Centre Singapore (NCCS) from February to April 2025. Validated questionnaires were administered electronically, and data were analyzed using descriptive, bivariate and multivariate methods using IBM SPSS Statistics 30.0.

Results

A total of 111 HCPs and 202 patients were surveyed. HCPs demonstrated moderate knowledge (60.8%) and confidence (59%) but generally positive attitudes. Patients showed limited knowledge (15.7%), generally neutral attitudes, and low confidence (35%). Occupation was the strongest predictor of HCPs’ knowledge, attitudes, and confidence, while higher education was associated with greater patient knowledge. HCPs confidence in efficacy was independently predicted by knowledge (aOR = 1.18), while confidence in safety was linked to attitudes (aOR = 1.34). For patients, higher knowledge correlated with greater safety confidence (p < 0.05).

Conclusion

Institutional mandates ensure strong biosimilar adoption, yet HCPs require further education to strengthen foundational understanding. For patients, low awareness and confidence are key barriers. Enhancing education and capitalising on the high levels of trust in HCPs may support transparent and confident decision-making in biosimilar use.

Keywords

Get full access to this article

View all access options for this article.

References

Chan

JCN

Chan

ATC

. Biologics and biosimilars: what, why and how? ESMO Open 2017; 2: e000180.

European Medicines Agency and European Commission. Biosimilars in the EU: information guide for healthcare professionals. 2023.

Makurvet

. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov 2021; 9: 100075.

CAS. The rise of biologics: emerging trends and opportunities. Columbus, OH: American Chemical Society, 2023.

Precedence Research. Biologics market size, share and trends 2026 to 2035, https://www.precedenceresearch.com/biologics-market (2026, accessed 11 March 2026).

World Health Organization. Biosimilars: expanding access to essential biologic therapies, https://www.who.int/news/item/13-02-2025-biosimilars–expanding-access-to-essential-biologic-therapies (2025, accessed 11 March 2026).

U.S. Food & Drug Administration. Biosimilar and interchangeable biologics: more treatment choices, https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices (2023, accessed 11 March 2026).

Tan

Goh

LGH

Ong

BSK

, et al. Impact of value-driven healthcare strategies for biosimilar adoption: the Singapore story. Pharmacoecon Open 2024; 8: 679–688.

Ministry of Health Singapore. Subsidies for drugs on the Standard Drug List (SDL) at Public Healthcare Institutions, https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/subsidies-for-drugs-on-the-standard-drug-list-(sdl)-at-public-healthcare-institutions/ (2025, accessed 11 March 2026).

10.

Ministry of Health Singapore. Subsidies for drugs on the Medication Assistance Fund (MAF) List at Public Healthcare Institutions, https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/subsidies-for-drugs-on-the-medication-assistance-fund-(maf)-list-at-public-healthcare-institutions/ (2024, accessed 11 March 2026).

11.

Agency for Care Effectiveness. Who we are, https://www.ace-hta.gov.sg/about-us/who-we-are/ (2025, accessed 11 March 2026).

12.

Azuz

Newton

Bartels

, et al. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars. Eur J Clin Pharmacol 2021; 77: 1495–1501.

13.

Halimi

Daci

Ancevska Netkovska

, et al. Clinical and regulatory concerns of biosimilars: a review of literature. Int J Environ Res Public Health 2020; 17: 5800.

14.

Ajzen

. The theory of planned behavior. Organ Behav Hum Decis Process 1991; 50: 179–211.

15.

Lynn

. Determination and quantification of content validity. Nurs Res 1986; 35: 382–385.

16.

Ruel

Wagner

Gillespie

. Pretesting and pilot testing. In: The practice of survey research: theory and applications. Los Angeles, CA: Sage Publications, Inc, 2016, pp.103–125.

17.

Yusoff

MSB

. ABC Of response process validation and face validity index calculation. Education in Medicine Journal 2019; 11: 55–61.

18.

Collins

. Research design and methods. In: Birren

(ed.) Encyclopedia of gerontology. 2nd ed. Amsterdam; Boston: Elsevier, 2007, pp.433–442.

19.

Cochran

. Sampling techniques. 3rd ed. New York: John Wiley and Sons Inc., 1977.

20.

Hosmer

Lemeshow

. Applied logistic regression. 1st ed. John Wiley & Sons, Inc., 2000.

21.

Edwards

Tatterton

. Barriers and facilitators to primary care staff conducting research – a qualitative systematic review. Eur J Gen Pract 2025; 31: 2539777.

22.

Ellis

Pomare

Churruca

, et al. Predictors of response rates of safety culture questionnaires in healthcare: a systematic review and analysis. BMJ Open 2022; 12: e065320.

23.

Matheson

Skinner

Vehagen

, et al. Barriers and enablers of primary healthcare professionals in health research engagement: a systematic review of qualitative studies. Nurs Health Sci 2025; 27: e70022.

24.

Gasteiger

Petrie

. Pharmacists’ confidence in explaining biosimilars to patients before a nationwide medicine change: a cross-sectional study. Explor Res Clin Soc Pharm 2022; 8: 100199.

25.

Song

Jiang

, et al. Knowledge, attitudes and practice of healthcare providers, healthcare regulatory practitioners and patients toward biosimilars in China: insights from a nationwide survey. Front Pharmacol 2022; 13: 876503.

26.

Leonard

Wascovich

Oskouei

, et al. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm 2019; 25: 102–112.

27.

Rosembert

Twigg

Wright

. Patient's and consultant's views and perceptions on switching from an originator biologic to biosimilar medication: a qualitative study. Pharmacy (Basel) 2024; 12: 65.

28.

Thongpooswan

Das

Patil

, et al. Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian countries: a survey study. Expert Opin Biol Ther 2024; 24: 1171–1182.

29.

Wang

, et al. Patients’ perceptions of biosimilars: a systematic review. BioDrugs 2023; 37: 829–841.

30.

Gaglio

Glasgow

Bull

. Do patient preferences for health information vary by health literacy or numeracy? A qualitative assessment. J Health Commun 2012; 17: 109–121.

31.

Chen

Hay

Waters

, et al. Health literacy and use and trust in health information. J Health Commun 2018; 23: 724–734.

32.

Jacobs

Singh

Sewell

, et al. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence 2016; 10: 937–948.

33.

Ryan

Cohen-Mekelburg

Baker

, et al. Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease. BMC Health Serv Res 2024; 24: 1209.

34.

Feldma

Reilly

. A white paper: uS biosimilars market on pace with Europe. GaBI J 2020; 9: 150–154.

35.

Seals

. Healthcare professionals knowledge and attitudes regarding biosimilars in Northern Mississippi . Thesis, University of Mississppi, Sally McDonnell Barksdale Honors College, 2017.

36.

Okoro

. Biosimilar medicines uptake: the role of the clinical pharmacist. Explor Res Clin Soc Pharm 2021; 1: 100008.

37.

Naito

. Uniting for greater impact: the crucial role of oncology nurses in cancer care. Asia Pac J Oncol Nurs 2024; 11: 100370.

38.

Heradstveit

Larsen

Solberg

, et al. Critical care nurses’ role in the decision-making process of withdrawal of life-sustaining treatment: a qualitative systematic review. J Clin Nurs 2023; 32: 6012–6027.

39.

Pueyo-Garrigues

Pardavila-Belio

Canga-Armayor

, et al. NURSES’ knowledge, skills and personal attributes for providing competent health education practice, and its influencing factors: a cross-sectional study. Nurse Educ Pract 2022; 58: 103277.

40.

Wilandika

Pandin

MGR

Yusuf

. The roles of nurses in supporting health literacy: a scoping review. Front Public Health 2023; 11: 1022803.

41.

Friganović

Mędrzycka-Dąbrowska

Krupa

, et al. Nurses’ knowledge and attitudes towards biosimilar medicines as part of evidence-based nursing practice-international pilot study within the project biosimilars nurses guide version 2.0. Int J Environ Res Public Health 2022; 19: 10311.

42.

Kim

Seomun

. Exploring the knowledge structure of patient safety in nursing using a keyword network analysis. Comput Inform Nurs 2023; 41: 67–76.

43.

Konstantinidou

Papaspiliou

Kokkotou

. Current and future roles of biosimilars in oncology practice. Oncol Lett 2020; 19: 45–51.

44.

Schunk

Dibenedetto

. Learning from a social cognitive theory perspective. 2022, pp.22–35.

45.

Garrison

Karlsson

Fressard

, et al. International adaptation and validation of the Pro-VC-Be: measuring the psychosocial determinants of vaccine confidence in healthcare professionals in European countries. Expert Rev Vaccines 2023; 22: 726–737.

46.

Chipidza

Wallwork

Stern

. Impact of the doctor-patient relationship. Prim Care Companion CNS Disord 2015; 17. DOI: 10.4088/PCC.15f01840.

47.

Giles

Lewis

Phipps

, et al. Capturing patients’ perspectives on medication safety: the development of a patient-centered medication safety framework. J Patient Saf 2020; 16: e324–e339.

48.

Gokul

Kumar

Kamaraj

. The biosimilar revolution: assessing the European Union's approach to biosimilarity, interchangeability, patient access, and its market analysis. Cureus 2024; 16: e68103.

49.

Poon

Hsu

, et al. Assessing knowledge and attitude of healthcare professionals on biosimilars: a national survey for pharmacists and physicians in Taiwan. Healthcare (Basel) 2021; 9: 1600.

50.

Pavlovic

Sahoo

Larson

, et al. Factors influencing healthcare professionals’ confidence in vaccination in Europe: a literature review. Hum Vaccin Immunother 2022; 18: 2041360.

51.

Rieger

Dean

Hall

, et al. Barriers and enablers affecting the uptake of biosimilar medicines viewed through the lens of actor network theory: a systematic review. BioDrugs 2024; 38: 541–555.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.13 MB

0.00 MB